Journals / Eurasian Journal of Critical Care / 2022 / Cilt: 4 - Sayı: 3
Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19
- Pages
- 116–118
- DOI
- —
Abstract
The novel coronavirus disease 2019 (COVID-19) emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.